HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease

Jeremy Adler*, Joseph A. Galanko, Rana Ammoury, Keith J. Benkov, Athos Bousvaros, Brendan Boyle, José M. Cabrera, Kelly Y. Chun, Jill Dorsey, Dawn R. Ebach, Ann M. Firestine, Ajay S. Gulati, Hans H. Herfarth, Traci W. Jester, Jess L. Kaplan, Ian Leibowitz, Tiffany M. Linville, Peter A. Margolis, Phillip Minar, Zarela Molle-RiosJonathan Moses, Kelly Olano, Dinesh S. Pashankar, Lisa Pitch, Shehzad A. Saeed, Charles M. Samson, Kelly Sandberg, Steven J. Steiner, Jennifer A. Strople, Jillian S. Sullivan, Prateek D. Wali, Michael D. Kappelman

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Agricultural and Biological Sciences